Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Bristol-Myers Squibb
Bristol-Myers Squibb
Seagen Inc.
Taiho Oncology, Inc.
Servier
Sumitomo Pharma America, Inc.
Curis, Inc.
Shattuck Labs, Inc.
Faron Pharmaceuticals Ltd
Prelude Therapeutics
Novartis
Kahr Medical
Ellipses Pharma
Bristol-Myers Squibb
BlossomHill Therapeutics
AbbVie
Eli Lilly and Company
Cyclacel Pharmaceuticals, Inc.
Ono Pharmaceutical Co. Ltd
AbbVie
Prelude Therapeutics
Cyclacel Pharmaceuticals, Inc.